Nov. 12, 2012
Simcere Pharma was given SFDA approval to begin clinical trials in China for BD0801, an anti-angiogenesis drug that will be tested as a treatment for cancer. The IND for the molecule was filed in March 2011. Simcere partners with Apexigen, a Californian company that developed a rabbit-based monoclonal antibody platform. Simcere owns China rights to BD0801, which will be the first of Apexigen’s molecules to start human trials.